source
- FDA advisory panels for Capricor and Replimune highlight need for rare-disease specialist inputRecent FDA advisory committee meetings reviewing therapies from Capricor Therapeutics and Replimune produced markedly different outcomes, underscoring how the agency’s reliance on specialist input…
- K Health plans IPO by 2029 after recent funding roundK Health, a virtual‑care company that uses AI, announced its intention to go public by 2029. CEO Allon Bloch made the comment after a recent fundraising round, signalling the firm is preparing for…